Faron Pharmaceuticals Oy (LON:FARN – Get Free Report)’s share price hit a new 52-week low during trading on Tuesday. The stock traded as low as GBX 29 and last traded at GBX 30.50, with a volume of 53,958 shares changing hands. The stock had previously closed at GBX 31.50.
Faron Pharmaceuticals Oy Stock Performance
The company has a quick ratio of 1.09, a current ratio of 2.40 and a debt-to-equity ratio of 154.15. The business has a 50 day simple moving average of GBX 35.26 and a two-hundred day simple moving average of GBX 51.58. The firm has a market cap of £58.84 million, a PE ratio of -2.52 and a beta of 1.12.
Faron Pharmaceuticals Oy Company Profile
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
See Also
- Five stocks we like better than Faron Pharmaceuticals Oy
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
